Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.54 |
| ▸ | CD79B | P40259 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345790 | 1.00 | NT5E (0.54) | NT5ECD79BLMNATP53ADORA3 | |
| SCHEMBL23345791 | 1.00 | NT5E (0.54) | NT5ECD79BLMNATP53ADORA3 | |
| SCHEMBL23345645 | 0.88 | NT5E (0.53) | NT5ECD79B | |
| SCHEMBL23345647 | 0.88 | NT5E (0.53) | NT5ECD79B | |
| SCHEMBL22856800 | 0.86 | NT5E (0.70) | NT5ECD79B | |
| SCHEMBL22856823 | 0.86 | NT5E (0.70) | NT5ECD79B | |
| SCHEMBL22856799 | 0.86 | NT5E (0.70) | NT5ECD79B | |
| SCHEMBL26281966 | 0.86 | NT5E (0.70) | NT5ECD79B | |
| SCHEMBL23345957 | 0.81 | NT5E (0.76) | NT5ECD79BADORA3 | |
| SCHEMBL23345956 | 0.81 | NT5E (0.76) | NT5ECD79BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885CD79B 2970/4885LMNA 2144/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885CD79B 2970/4885LMNA 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.